last quarter they did 644 mill and guided to 12-15% sequential growth, or 721-740 mill, and they hit 738, or the higher end of the scale. Now they are guiding in-line so they should exceed the 704 by a few mill. I think 2014 will see accelerating earnings and revenues. It is still a buy.
and then this:
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI.
Mental Health Research Institute, The University of Melbourne, Parkville, VIC, Australia.
PBT2 is a copper/zinc ionophore that rapidly restores cognition in mouse models of Alzheimer's disease (AD). A recent Phase IIa double-blind, randomized, placebo-controlled trial found that the 250 mg dose of PBT2 was well-tolerated, significantly lowered cerebrospinal fluid (CSF) levels of amyloid-beta42, and significantly improved executive function on a Neuro-psychological Test Battery (NTB) within 12 weeks of treatment in patients with AD. In the post-hoc analysis reported here, the cognitive, blood marker, and CSF neurochemistry outcomes from the trial were subjected to further analysis. Ranking the responses to treatment after 12 weeks with placebo, PBT2 50 mg, and PBT2 250 mg revealed that the proportions of patients showing improvement on NTB Composite or Executive Factor z-scores were significantly greater in the PBT2 250 mg group than in the placebo group. Receiver-operator characteristic analyses revealed that the probability of an improver at any level coming from the PBT2 250 mg group was significantly greater, compared to placebo, for Composite z-scores (Area Under the Curve [AUC] =0.76, p=0.0007), Executive Factor z-scores (AUC =0.93, p=1.3 x 10(-9)), and near-significant for the ADAS-cog (AUC =0.72, p=0.056). There were no correlations between changes in CSF amyloid-beta or tau species and cognitive changes. These findings further encourage larger-scale testing of PBT2 for AD.
no you haven't, rt. You are correct, and your wisdom shall be rewarded handsomely. ;-)
In all seriousness, I agree with you. PRAN is still very much undiscovered, in part because it is an offshore company, in part because it is chasing a disease that is riddled with drug failures, and in part because very few investors have researched metal protein attenuating compounds like PBT2. Here is a summary from the NIH:
"Alzheimer’s disease (AD), the most common form of dementia in the elderly, is characterized by elevated brain iron levels and accumulation of copper and zinc in cerebral β-amyloid deposits; e.g., senile plaques. Both ionic zinc and copper are able to accelerate the aggregation of Aβ, the principle component of β-amyloid deposits. Copper (and iron) can also promote the neurotoxic redox activity of Aβ and induce oxidative cross-linking of the peptide into stable oligomers. Recent reports have documented the release of Aβ together with ionic zinc and copper in cortical glutamatergic synapses following excitation. This, in turn, leads to the formation of Aβ oligomers, which, in turn, modulate long-term potentiation (by controlling synaptic levels of the NMDA receptor). The excessive accumulation of Aβ oligomers in the synaptic cleft would then be predicted to adversely affect synaptic neurotransmisson. Based on these findings, we have proposed the “Metal Hypothesis of Alzheimer’s Disease” which stipulates that the neuropathogenic effects of Aβ in AD are promoted by, and possibly even dependent upon Aβ-metal interactions. Increasingly sophisticated pharmaceutical approaches are now being implemented to attenuate abnormal Aβ-metal interactions without causing systemic disturbance of essential metals. Small molecules targeting Aβ–metal interactions, e.g. PBT2, are currently advancing through clinical trials and show increasing promise as disease-modifying agents for AD based on the “metal hypothesis”.
very transparent short post. A long would never post this without some facts behind it. It didn't open up this morning with a large drop, and there is no news to suggest it might tomorrow, so your post is merely a stupid scare tactic, as if it matters.
I think PBT2 will be the start of a whole new class of drugs that work on metal imbalances. My bet right now is that PBT2 in HD failed to show statistical significance, while in AD it will. I think that's why they delayed the HD results - so they can mine for a successful subgroup and then present both data sets - HD and AD - at one time, leading with the success of the AD trial. That's the only way to keep the stock price from imploding. Of course, if they release successful data from HD early - this stock will absolutely explode upward. I am hoping for a 10 bagger at least here.
Sentiment: Strong Buy
I think both RMTI and KERX get taken out in 2014. Fresenius and DaVita would be two candidates, but there are many, including Amgen. Both co's should sell north of $30/share.
well, the shares soared past $6 to $6.89 just a day earlier - they probably could have gotten away with a $6 price instead of $5.50!
Regardless of the reasons that this priced at $4.80, I think Oppenheimer left money on the table for NWBO. This should have been priced at $5.50 and there would have been plenty of demand. I think Linda Powers threw Oppenheimer a good deal because of her past dealings with CIBC and Oppenheimer when she was global finance VP at Enron: "On November 4, 2007, CIBC announced from Toronto that they agreed to sell to Oppenheimer & Co. its U.S. domestic investment banking, equities, leveraged finance and related debt capital markets businesses. The transaction also included CIBC's Israeli investment banking and equities business, and certain parts of other U.S. capital markets-related businesses located in the UK and Asia. The formal agreement dictated that Oppenheimer would borrow $100 million from CIBC in the form of a subordinated debt as well warehouse facility provided by the Canadian bank. The warehousing facility initially up to $1.5 billion would allow the newly formed Oppenheimer U.S. entity to finance and hold the syndicated loans for U.S. middle market companies. Underwriting of loans pursuant to the warehouse facility will be subject to joint credit approval by Oppenheimer and CIBC. In doing so, CIBC would benefit from the future success of Oppenheimer & Co. Some speculated that this sale was the result of the 2005 settlement of the civil lawsuits related to CIBC's entanglement with Enron for about $3 billion. It was one of the largest such settlements to date and believed to adversely affect CIBC operations. For many CIBC World Markets employees who remained from the original Oppenheimer & Co., the sale was reunification of sorts. The deal closed on January 14, 2008, yet both entities will share infrastructure for sometime and possibly office buildings. This includes 300 Madison Avenue, the building once set out to be the New York, CIBC Center..."
Oh, and backlog in 2007 was around $112 million. Now it's $145 million and climbing. I've been tracking this since $7, but for a variety of reasons didn't buy until now. I mainly wanted to see a solid and sustained breakout in their revenues.
Seventy-eight participants with early stage Alzheimer's disease took either 50mg or 250mg doses of the drug PBT2, or a placebo, over the course of 12 weeks in a randomised, double-blind clinical trial, led by a researcher from Imperial College London working with colleagues in Australia and Sweden. Both doses of PBT2 capsules were observed to be safe and well tolerated during the course of the study.
Participants undertook a number of tests to assess their cognitive function, prior to beginning treatment and at the end of the 12-week period. In two of these tests of executive function, which involves the ability to organise information, sequence events and plan, those on a 250mg dose of PBT2 showed a significant improvement over the placebo group.
The researchers also measured how the levels of amyloid-beta in spinal fluid changed during the course of the trial. They found that levels of amyloid-beta 42 in the cerebrospinal fluid of those on the 250mg dose of PBT2 were reduced by approximately 13 percent compared to placebo at the end of the 12-week period.
Amyloid-beta needs the metals zinc and copper in order to accumulate in the brain and these two metals become abnormally distributed in the brains of people with Alzheimer's disease. PBT2 works by interrupting the interaction between the metal ions and amyloid-beta, and returns levels of zinc and copper in the brain to normal levels.
In the cognitive tests, those on a 250mg dose of PBT2 were able to complete the task in a test known as Trail Making Part B an average of 42 seconds faster than they had at the beginning of the trial. The placebo group was an average of 6 seconds slower.
In the Category Fluency Test, which looks at a person's ability to come up with as many relevant words as possible in relation to a specified category, those in the 250mg group were able to produce an average of 2.4 more words than at the beginning of the trial. This compared with a decrease of 0.3 words in the placebo group.
Small numbers, amazing anecdotal success stories. PBT2 is one of the first drugs not to attack symptoms, but cause. I think this is going to fly to $10 before results are released.
Sentiment: Strong Buy
Money - was in ANIK? Another biotech? I've been off and on these boards for years, so very well could be. Best to you as well.
That dip you saw from $119 to $116 and back? that was a managed short exit - Almost a million shares traded hands in that dip - that was 80% of the shorts exiting - less than a million shares are short. This thing has legs now.